a randomized parallel-group, placebo-controlled, double-blind, event-driven, multi-
center pivotal phase iii clinical outcome trial of efficacy and safety of the oral sgc
stimulator vericiguat in subjects with heart failure with reduced ejection fractio
|
11-11-201610-08-2020
|
Penyelidik Bersama
|
cardiovascular screening for detection of risk factors for premature coronary heart disease and sudden cardiac death among universiti kebangsaan malaysia students
|
16-05-201915-11-2019
|
Penyelidik Bersama
|
a study on prevalence of acute coronary syndrome influenced by diabetes mellitus among the coronary care unit patients at teaching hospital
|
27-06-201926-09-2019
|
Penyelidik Bersama
|
malaysia st-elevation myocardial infarction (mystemi) network program
|
12-05-201611-05-2019
|
Penyelidik Bersama
|
a randomized, double blind, placebo-controlled, parallel-group study of evaluate the effect of alirocumab (sar236553/regn727) on the occurrence of cardiovascular events in patients who have recently experienced an acute coronary syndrome
|
01-04-201330-04-2019
|
Penyelidik Bersama
|
a randomized, double-blind, event-driven, multicenter study comparing the efficacy and safety of rivaroxaban with placebo for reducing the risk of death, myocardial infarction or stroke in subjects with heart failure and significant coronary artery
|
09-07-201508-01-2019
|
Penyelidik Bersama
|
non-interventional study describing patients´ perception on anticoagulant treatment and treatment convenience when treated with pradaxa® or vitamin k antagonist for stroke prophylaxis in atrial fibrillation
|
15-09-201614-12-2018
|
Penyelidik Bersama
|
a multicenter, randomized, double-blind, placebo-controlled phase iii study to evaluate the efficacy, safety and tolerability of serelaxin when added to standard therapy in acute heart failure patients. protocol no : crlx030a2302
|
05-12-201404-06-2018
|
Penyelidik Bersama
|
coroflex isar (international registry)
|
28-09-201431-12-2017
|
Penyelidik Bersama
|